5 Texas entrepreneurs rank among Forbes' richest self-made women

Must be the money

Kendra Scott is one of the five richest self-made women in the state. Photo by Tyler Schmitt, ARF

It's common knowledge Houston Rockets owner Tilman Fertitta and Gulf States Toyota owner Dan Friedkin rank among the wealthiest people in Texas. But did you know that five other entrepreneurs — collectively worth more than $4 billion — stand among the richest self-made women in the country?

Billionaire Thai Lee and millionaires Kendra Scott, Kathleen Hildreth, Whitney Wolfe Herd, and Suzy Batiz appear on Forbes magazine's new list of America's 80 richest self-made women — women who garnered wealth on their own, rather than by inheriting or winning it. And they're in great company, joining the likes of Taylor Swift, Oprah Winfrey, Kylie Jenner, Rihanna, Madonna, Celine Dion, and Beyoncé.

Thai Lee, with an estimated net worth of $3 billion, appears at No. 5 on the Forbes list. She is president and CEO of SHI International Corp., a provider of IT products and services whose more than 17,000 customers include AT&T and Boeing. Revenue at the New Jersey-based company hit $10 billion in 2018; more than 4,000 people work at SHI. Austin is home to SHI's corporate call center and is the hub for its sales division catering to small and midsize businesses.

"In early 2015, we mapped a five-year goal to reach $10 billion in revenue by the end of 2019. Through the hard work of our employees, the strength of our partnerships, and our ability to discern and solve our customers' most pressing IT and business challenges, we reached that goal 12 months early," Lee says in a February release.

At No. 40 on the list, with an estimated net worth of $550 million, is Kendra Scott. She is founder and CEO of Kendra Scott Design Inc. Annual sales at the Austin-based jewelry company hover around $360 million.

In 2017, Boston-based private equity firm Berkshire Partners invested in Scott's company at a valuation of more than $1 billion. Scott started the company in 2002 in the spare bedroom of her home. Today, Scott's business operates 100 jewelry stores, runs massive e-commerce and wholesale units, and employs more than 2,000 people. Last year, the company opened its flagship store on South Congress Avenue.

"There were so many ups and downs through this journey. There were many times that I thought I was going to lose my business. I had no investment capital. I was carrying it all on my shoulders — bootstrapping it, literally," Scott told CNN in 2018.

Kathleen Hildreth, co-founder of aviation-maintenance company M1 Support Services, appears on the list at No. 57, with an estimated net worth of $370 million. She is a West Point graduate and Army veteran who served as a helicopter pilot. Before M1 Support, she worked with defense contractors, including Lockheed Martin and DynCorp. Hildreth calls Aubrey, Texas, in the DFW area, home.

"Anything in the government's [aircraft] inventory, we do work on," Hildreth told Forbes. "You name it." Forbes adds, "The U.S Air Force, U.S. Army, U.S. Navy, and NASA are all clients of M1 Support, which relies entirely on the federal government for business. Most of its revenues come from maintaining military aircraft, including fighter jets such as F15s, F16s, and A10 Thunderbolts."

The fourth Texas entrepreneur on the list is Whitney Wolfe Herd, founder and CEO of Austin-based Bumble Trading Inc., developer of the Bumble dating app for women, and the related Bumble BFF friend-finding app and Bumble Bizz networking app. Herd launched Bumble in 2014 after co-founding dating app Tinder. With an estimated net worth of $290 million, Herd claimed the No. 72 spot on the Forbes list. This is her first year to be ranked.

Bumble counts more than 60 million users in 150 countries. The company's estimated annual revenue totals $175 million, according to Forbes. Russian billionaire Andrey Andreev is the majority owner of Bumble.

"I want to take this sucker around the planet," Herd told Marie Claire last year about the future of Bumble. "Then, who knows, maybe we'll work with [Jeff] Bezos and [Elon] Musk and take it beyond."

At No. 77, with an estimated net worth of $270 million, is Dallas' Suzy Batiz, founder of Poo-Pourri, the before-you-go toilet spray available at major retailers. More than 60 million bottles have sold since the company's founding in 2007; Pou-Pourri is now expanding into shoe and pet odors and a cleaning line.

Asked in 2016 what the riskiest thing was she had ever done professionally, Batiz said not selling her company or taking on investors.

"I had no idea if it was going to work out. It's like being on a game show," she told Forbes. "They hand you the big briefcase and you think, 'You can take this thing of money, or you can gamble and try to stay in the game.' Somehow I knew that my baby, the company, was very similar to a child. It just wasn't ready to be released into the world yet without me."

---

This story originally appeared on CultureMap.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings